The Journal of Immunology, Vol 156, Issue 1 246-255, Copyright © 1996 by American Association of Immunologists

ARTICLES

Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response

BM Mitchell and JG Stevens
Department of Microbiology and Immunology, University of California, Los Angeles, School of Medicine 90024, USA.

Neuroinvasiveness is a property central to the pathogenesis of herpes simplex virus (HSV) and most isolates demonstrate this property. Exceptions are HSV strains KOS and ANG, for which we have previously shown that the non-neuroinvasive phenotype is referable to single amino acid changes in glycoprotein D for ANG or glycoprotein B for KOS. Because glycoproteins B and D are immunologically significant, the possibility that the phenotype has an immunologic basis was examined. Nonimmunosuppressed mice could not be killed with any dose of these non- neuroinvasive viruses after footpad inoculation, but in cyclophosphamide-suppressed animals, the ratios of plaque-forming units to LD50 decreased by at least four orders of magnitude to levels comparable with that of ANG-path, a neuroinvasive derivative of ANG. KOS and ANG induced a more rapid circulating neutralizing Ab response than did ANG-path, and mice were protected when these agents were co- infected with the neuroinvasive strain. The noninvasive viruses engendered an enhanced mononuclear cell infiltrate in infected spinal ganglia which consisted of increased numbers of CD4+ and CD8+ T cells and an increased production and secretion of IgG. HSV-specific Ab- secreting cells were also observed. In addition, passive transfer of anti-HSV mouse serum protected immunosuppressed mice from lethal HSV challenge. Selective in vivo depletion of T lymphocytes increased the detectable levels of both KOS and ANG viruses in the spinal ganglia at 6 days postinfection, but it did not alter the ratios of plaque-forming units to LD50 or affect the HSV-induced increase in ganglionic IgG. Taken together, these data indicate that in these systems there is an immunologic basis for the control of HSV-1 neuroinvasiveness and that humoral, rather than cell-mediated immunity, is playing the major role.

This article has been cited by other articles:

				P. P. Sarangi, B. Kim, E. Kurt-Jones, and B. T. Rouse Innate Recognition Network Driving Herpes Simplex Virus-Induced Corneal Immunopathology: Role of the Toll Pathway in Early Inflammatory Events in Stromal Keratitis J. Virol., October 15, 2007; 81(20): 11128 - 11138. [Abstract] [Full Text] [PDF]

				A. Calistri, P. Sette, C. Salata, E. Cancellotti, C. Forghieri, A. Comin, H. Gottlinger, G. Campadelli-Fiume, G. Palu, and C. Parolin Intracellular Trafficking and Maturation of Herpes Simplex Virus Type 1 gB and Virus Egress Require Functional Biogenesis of Multivesicular Bodies J. Virol., October 15, 2007; 81(20): 11468 - 11478. [Abstract] [Full Text] [PDF]

				Y. Osorio and H. Ghiasi Recombinant Herpes Simplex Virus Type 1 (HSV-1) Codelivering Interleukin-12p35 as a Molecular Adjuvant Enhances the Protective Immune Response against Ocular HSV-1 Challenge J. Virol., March 15, 2005; 79(6): 3297 - 3308. [Abstract] [Full Text] [PDF]

				I. Beitia Ortiz de Zarate, K. Kaelin, and F. Rozenberg Effects of Mutations in the Cytoplasmic Domain of Herpes Simplex Virus Type 1 Glycoprotein B on Intracellular Transport and Infectivity J. Virol., February 1, 2004; 78(3): 1540 - 1551. [Abstract] [Full Text] [PDF]

				C. Potel, K. Kaelin, L. Danglot, A. Triller, C. Vannier, and F. Rozenberg Herpes simplex virus type 1 glycoprotein B sorting in hippocampal neurons J. Gen. Virol., October 1, 2003; 84(10): 2613 - 2624. [Abstract] [Full Text] [PDF]

				J. Neumann, A. M. Eis-Hubinger, and N. Koch Herpes Simplex Virus Type 1 Targets the MHC Class II Processing Pathway for Immune Evasion J. Immunol., September 15, 2003; 171(6): 3075 - 3083. [Abstract] [Full Text] [PDF]

				H. Mao and K. S. Rosenthal Strain-Dependent Structural Variants of Herpes Simplex Virus Type 1 ICP34.5 Determine Viral Plaque Size, Efficiency of Glycoprotein Processing, and Viral Release and Neuroinvasive Disease Potential J. Virol., March 15, 2003; 77(6): 3409 - 3417. [Abstract] [Full Text] [PDF]

				L. Kercher and B. M. Mitchell Persisting Murine Cytomegalovirus Can Reactivate and Has Unique Transcriptional Activity in Ocular Tissue J. Virol., August 12, 2002; 76(18): 9165 - 9175. [Abstract] [Full Text] [PDF]

				S.-I. Tschen, C. C. Bergmann, C. Ramakrishna, S. Morales, R. Atkinson, and S. A. Stohlman Recruitment Kinetics and Composition of Antibody-Secreting Cells Within the Central Nervous System Following Viral Encephalomyelitis J. Immunol., March 15, 2002; 168(6): 2922 - 2929. [Abstract] [Full Text] [PDF]

				B. M. Mitchell and R. L. Font Detection of Varicella Zoster Virus DNA in Some Patients with Giant Cell Arteritis Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2572 - 2577. [Abstract] [Full Text] [PDF]

				D. J.J. Carr, P. Härle, and B. M. Gebhardt The Immune Response to Ocular Herpes Simplex Virus Type 1 Infection Experimental Biology and Medicine, May 1, 2001; 226(5): 353 - 366. [Abstract] [Full Text]

				P. V. Coyle, S. Jain, D. Wyatt, C. McCaughey, and H. J. O'Neill Description of a Nonlethal Herpes Simplex Virus Type 1 Glycoprotein D Deletion Mutant Affecting a Site Frequently Used for PCR Clin. Vaccine Immunol., March 1, 2000; 7(2): 322 - 324. [Abstract] [Full Text] [PDF]

				J. R. Bower, H. Mao, C. Durishin, E. Rozenbom, M. Detwiler, D. Rempinski, T. L. Karban, and K. S. Rosenthal Intrastrain Variants of Herpes Simplex Virus Type 1 Isolated from a Neonate with Fatal Disseminated Infection Differ in the ICP34.5 Gene, Glycoprotein Processing, and Neuroinvasiveness J. Virol., May 1, 1999; 73(5): 3843 - 3853. [Abstract] [Full Text]

				J. E. Blaney Jr., E. Nobusawa, M. A. Brehm, R. H. Bonneau, L. M. Mylin, T.-M. Fu, Y. Kawaoka, and S. S. Tevethia Immunization with a Single Major Histocompatibility Complex Class I-Restricted Cytotoxic T-Lymphocyte Recognition Epitope of Herpes Simplex Virus Type 2 Confers Protective Immunity J. Virol., December 1, 1998; 72(12): 9567 - 9574. [Abstract] [Full Text] [PDF]

				J. L. Beland, H. Adler, N. C. Del-Pan, W. Kozlow, J. Sung, W. Fanslow, and I. J. Rimm Recombinant CD40L Treatment Protects Allogeneic Murine Bone Marrow Transplant Recipients From Death Caused by Herpes Simplex Virus-1 Infection Blood, December 1, 1998; 92(11): 4472 - 4478. [Abstract] [Full Text] [PDF]

				K. Goldsmith, W. Chen, D. C. Johnson, and R. L. Hendricks Infected Cell Protein (ICP)47 Enhances Herpes Simplex Virus Neurovirulence by Blocking the CD8+ T Cell Response J. Exp. Med., February 2, 1998; 187(3): 341 - 348. [Abstract] [Full Text] [PDF]